{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:51:14Z","timestamp":1769637074864,"version":"3.49.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Epidermolysis bullosa is a hereditary skin disorder characterized by skin fragility. However, the disease can manifest in many different organ systems, therefore children born with epidermolysis bullosa may have life long, complex medical needs. In this review, we will use a system-based approach to highlight important aspects of disease management and recent advancements in each of the areas. In addition, we will overview some of the cutting edge therapeutic developments in epidermolysis bullosa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent advancements in supportive care of epidermolysis bullosa with focus on wound, pain, pruritus and nutrition status were discussed. Clinical surveillance and complication prevention are critical to improve clinical outcomes. Generalized epidermolysis bullosa is a systemic disease with increased morbidity and mortality; therefore, complex care using a multidisciplinary approach will provide the greatest benefits for patients. Current targeted treatments for epidermolysis bullosa aim at restoring the skin integrity using protein, cell, and gene therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Improvement in care of epidermolysis bullosa in recent years results from keen clinical observation, novel molecular targeting, and the embracement of translational research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000380","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T13:48:34Z","timestamp":1465566514000},"page":"507-516","source":"Crossref","is-referenced-by-count":36,"title":["Advancement in management of epidermolysis bullosa"],"prefix":"10.1097","volume":"28","author":[{"given":"Heather I.","family":"Cohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce M.C.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2012.01.016","article-title":"A consensus approach to wound care in epidermolysis bullosa","volume":"67","author":"Pope","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/pde.12492","article-title":"Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa","volume":"32","author":"Gorell","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/pde.12409","article-title":"Effectiveness of saltwater baths in the treatment of epidermolysis bullosa","volume":"32","author":"Petersen","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/AAC.00079-15","article-title":"High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population","volume":"59","author":"Antonov","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijmm.2013.11.012","article-title":"Host-pathogen interactions in epidermolysis bullosa patients colonized with Staphylococcus aureus","volume":"304","author":"van der Kooi-Pol","year":"2014","journal-title":"Int J Med Microbiol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1038\/ncomms6932","article-title":"Innate sensing of microbial products promotes wound-induced skin cancer","volume":"6","author":"Hoste","year":"2015","journal-title":"Nat Commun"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/exd.12152","article-title":"Serum levels of high mobility group box 1 correlate with disease severity in recessive dystrophic epidermolysis bullosa","volume":"22","author":"Petrof","year":"2013","journal-title":"Exp Dermatol"},{"key":"R9-20230918","article-title":"Expression and regulation of cathelicidin in keratinocytes from patients with epidermolysis bullosa","author":"Huettner","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/1523-1747.ep12471769","article-title":"Abnormalities of plasma and erythrocyte essential fatty acid composition in epidermolysis bullosa: influence of treatment with diphenylhydantoin","volume":"89","author":"Cunnane","year":"1987","journal-title":"J Invest Dermatol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2230.2008.02789.x","article-title":"A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa","volume":"34","author":"Langan","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/archderm.135.8.997","article-title":"Two familial cases of epidermolysis bullosa simplex successfully treated with tetracycline","volume":"135","author":"Retief","year":"1999","journal-title":"Arch Dermatol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1365-2133.2004.05816.x","article-title":"Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial","volume":"150","author":"Weiner","year":"2004","journal-title":"Br J Dermatol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjd.13672","article-title":"Oral erythromycin therapy in epidermolysis bullosa simplex generalized severe","volume":"173","author":"Chiaverini","year":"2015","journal-title":"Br J Dermatol"},{"issue":"(Suppl 1)","key":"R16-20230918","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1517\/14712598.2015.1011617","article-title":"Advances in the basic and clinical applications of thymosin \u03b24","volume":"15","author":"Goldstein","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1196\/annals.1415.017","article-title":"Epidermolysis bullosa: a genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin beta4","volume":"1112","author":"Fine","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jid.2015.10.050","article-title":"Progress toward treatment and cure of epidermolysis bullosa: summary of the DEBRA International Research Symposium EB2015","volume":"136","author":"Uitto","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R20-20230918","first-page":"27A","article-title":"The role of dermal skin substitutes in the management of hard to heal unusual wounds","author":"Williamson","year":"2002","journal-title":"Can J Plast Surg"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/archderm.136.10.1225","article-title":"Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds","volume":"136","author":"Falabella","year":"2000","journal-title":"Arch Dermatol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1067\/mjd.2003.502","article-title":"Graftskin therapy in epidermolysis bullosa","volume":"48","author":"Fivenson","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"264ra163","DOI":"10.1126\/scitranslmed.3009540","article-title":"Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","author":"Sebastiano","year":"2014","journal-title":"Sci Transl Med"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"264ra165","DOI":"10.1126\/scitranslmed.3010083","article-title":"Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Wenzel","year":"2014","journal-title":"Sci Transl Med"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/jid.2013.523","article-title":"Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa","volume":"134","author":"Tolar","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"264ra164","DOI":"10.1126\/scitranslmed.3009342","article-title":"Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa","volume":"6","author":"Umegaki-Arao","year":"2014","journal-title":"Sci Transl Med"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12916-014-0178-2","article-title":"Pain care for patients with epidermolysis bullosa: best care practice guidelines","volume":"12","author":"Goldschneider","year":"2014","journal-title":"BMC Med"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/pde.12391","article-title":"Prevalence and characterization of pruritus in epidermolysis bullosa","volume":"32","author":"Danial","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMc0906670","article-title":"Aprepitant as an antipruritic agent?","volume":"361","author":"Duval","year":"2009","journal-title":"N Engl J Med"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1534734615572469","article-title":"Epidermolysis bullosa pruriginosa: case series and review of the literature","volume":"14","author":"Kim","year":"2015","journal-title":"Int J Low Extrem Wounds"},{"key":"R34-20230918","first-page":"1035","article-title":"Underrecognition of epidermolysis bullosa pruriginosa","volume":"13","author":"Cha","year":"215","journal-title":"J Dtsch Dermatol Ges"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40257-015-0119-7","article-title":"Epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation","volume":"16","author":"Kim","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"R36-20230918","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.13406","article-title":"Dystrophic epidermolysis bullosa pruriginosa successfully treated with immunosuppressants","author":"Takahashi","year":"2016","journal-title":"J Dermatol"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.det.2010.01.010","article-title":"Nutrition for children with epidermolysis bullosa","volume":"28","author":"Haynes","year":"2010","journal-title":"Dermatol Clin"},{"key":"R38-20230918","first-page":"151","article-title":"Haematologic response of anaemic preschool children to ascorbic acid supplementation","volume":"39","author":"Seshadri","year":"1985","journal-title":"Hum Nutr Appl Nutr"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1749-6632.1975.tb29289.x","article-title":"Ascorbic acid and collagen synthesis in cultured fibroblasts","volume":"258","author":"Levene","year":"1975","journal-title":"Ann N Y Acad Sci"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2010.08.028","article-title":"Correlates of low bone mass in children with generalized forms of epidermolysis bullosa","volume":"65","author":"Bruckner","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-3476(98)70321-X","article-title":"Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin","volume":"132","author":"Fridge","year":"1998","journal-title":"J Pediatr"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1525-1470.2006.00314.x","article-title":"Darbepoetin alfa and ferric gluconate ameliorate the anemia associated with recessive dystrophic epidermolysis bullosa","volume":"23","author":"Kuo","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1525-1470.2010.01127.x","article-title":"Dilated cardiomyopathy in epidermolysis bullosa: a retrospective, multicenter study","volume":"27","author":"Lara-Corrales","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/J.JHSB.2004.07.006","article-title":"Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry, 1986\u20132002","volume":"30","author":"Fine","year":"2005","journal-title":"J Hand Surg Br"},{"key":"R46-20230918","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.det.2010.01.013","article-title":"Surgery of the hand in recessive dystrophic epidermolysis bullosa","volume":"28","author":"Bernardis","year":"2010","journal-title":"Dermatol Clin"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1055\/s-0034-1391308","article-title":"A two-step multidisciplinary approach to treat recurrent esophageal strictures in children with epidermolysis bullosa dystrophica","volume":"47","author":"Vowinkel","year":"2015","journal-title":"Endoscopy"},{"key":"R48-20230918","first-page":"421783","article-title":"Er:YAG laser dental treatment of patients affected by epidermolysis bullosa","volume":"2014","author":"Galeotti","year":"2014","journal-title":"Case Rep Dent"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/1346-8138.12559","article-title":"Surgical management with CO2 laser for pseudosyndactyly in recessive dystrophic epidermolysis bullosa","volume":"41","author":"Hasegawa","year":"2014","journal-title":"J Dermatol"},{"key":"R50-20230918","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1542\/peds.2014-1779","article-title":"Case report: rapidly healing epidermolysis bullosa wound after ablative fractional resurfacing","volume":"135","author":"Krakowski","year":"2015","journal-title":"Pediatrics"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.14104","article-title":"Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines","volume":"174","author":"Mellerio","year":"2016","journal-title":"Br J Dermatol"},{"key":"R52-20230918","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4161\/cbt.29482","article-title":"Kindler syndrome in mice and men","volume":"15","author":"Duperret","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"R53-20230918","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nm.3490","article-title":"Kindlin-1 controls Wnt and TGF-\u03b2 availability to regulate cutaneous stem cell proliferation","volume":"20","author":"Rognoni","year":"2014","journal-title":"Nat Med"},{"issue":"(Suppl 1)","key":"R54-20230918","first-page":"30","article-title":"Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa","volume":"25","author":"Kim","year":"2015","journal-title":"Eur J Dermatol"},{"key":"R55-20230918","doi-asserted-by":"crossref","first-page":"e0137639","DOI":"10.1371\/journal.pone.0137639","article-title":"Lysyl hydroxylase 3 localizes to epidermal basement membrane and is reduced in patients with recessive dystrophic epidermolysis bullosa","volume":"10","author":"Watt","year":"2015","journal-title":"PLoS One"},{"key":"R56-20230918","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/09546634.2014.915002","article-title":"Age and etiology of childhood epidermolysis bullosa mortality","volume":"26","author":"Hon","year":"2015","journal-title":"J Dermatolog Treat"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201608000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:12:03Z","timestamp":1695003123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201608000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000380","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}